Trial Profile
A 12-Week, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects With Dyslipidemia, Followed by a 40-Week Safety Extension Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2020
Price :
$35
*
At a glance
- Drugs Pitavastatin (Primary) ; Pravastatin
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms INTREPID
- Sponsors Kowa Research Institute
- 20 Apr 2020 Results published in the Journal of Infectious Diseases
- 19 Apr 2017 Results published in a Kowa Pharmaceutical Media Release.
- 01 Mar 2017 Resultsassessing efficacy published in the AIDS.